Trials / Recruiting
RecruitingNCT06519669
Autologous Tumor-Infiltrating Lymphocyte Injection(GT201) for Treatment of Patients with Advanced Lung Cancer
A Single-arm Clinical Study of Autologous Tumor-Infiltrating Lymphocyte (GT201 Injection ) for Treatment of Patients with Advanced Lung Cancer
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Grit Biotechnology · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study is a single arm, open design aimed at evaluating the safety and tolerability of Autologous Tumor-Infiltrating Lymphocyte (GT201 injection ) for treatment of patients with Advanced lung cancer,while evaluating pharmacokinetic characteristics and efficacy assessment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GT201 injection | GT201 injection to treat Advanced lung cancer |
Timeline
- Start date
- 2024-07-18
- Primary completion
- 2027-07-18
- Completion
- 2027-07-18
- First posted
- 2024-07-25
- Last updated
- 2025-02-17
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06519669. Inclusion in this directory is not an endorsement.